首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation fibrinolysis chemotactic activity and kinin generation.
【2h】

Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation fibrinolysis chemotactic activity and kinin generation.

机译:弗莱彻因子缺乏症。由于缺乏前激肽释放酶并伴有凝血纤维蛋白溶解趋化活性和激肽生成异常导致Hageman因子激活率降低。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fletcher factor-deficient plasma is deficient in prekallikrein and therefore generates no bradykinin upon activation with kaolin. It also possesses a diminished rate of kaolin-activable coagulation and fibrinolysis and possesses a defect in kaolin-activable chemotactic activity. These abnormalities are also corrected by reconstitution with purified prekallikrein. Addition of intact activated Hageman factor corrected the coagulation, fibrinolytic, and chemotactic defects and addition of Hageman factor fragments corrected the fibrinolytic defect and partially corrected the chemotactic defect; neither of these corrected the kinin-generating defect. Although the Hageman factor-dependent pathways appear to be initiated by contact activation of Hageman factor, the kallikrein generated activates more Hageman factor; this feedback is necessary for the Hageman factor-dependent pathways to proceed at a normal rate. It is the absence of this feedback in Fletcher factor-deficient plasma that accounts for the diminished rate of activation of Hageman factor and therefore a diminished rate of activation of the coagulation and fibrinolytic pathways. The ability of prekallikrein to correct the coagulation, fibrinolytic, kinin-generating, and chemotactic defects of Fletcher factor-deficient plasma is consistent with the identity of the Fletcher factor and prekallikrein.
机译:缺乏弗莱彻因子的血浆缺乏前激肽释放酶,因此在用高岭土激活时不会产生缓激肽。它还具有降低的高岭土可活化的凝结和纤维蛋白溶解的速率,并且具有高岭土可活化的趋化活性的缺陷。这些异常也可以通过用纯化的前激肽释放酶重建来纠正。加入完整的活化的Hageman因子可纠正凝血,纤溶和趋化性缺陷,添加Hageman片段可纠正纤维蛋白溶解性缺陷并部分纠正趋化性缺陷。这些都不能纠正激肽产生的缺陷。尽管依赖于哈格曼因子的途径似乎是由哈格曼因子的接触激活引发的,但是产生的激肽释放酶却激活了更多的哈格曼因子。这种反馈对于哈格曼因子依赖性途径以正常速度进行是必要的。缺乏弗莱彻因子的血浆中没有这种反馈,这说明了哈格曼因子的激活率降低,从而导致凝血和纤溶途径的激活率降低。前激肽释放酶纠正Fletcher因子缺乏型血浆的凝血,纤溶,激肽生成和趋化缺陷的能力与Fletcher因子和前激肽释放酶的身份一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号